Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2008
|
| gptkbp:ATCCode |
G04CA04
|
| gptkbp:brand |
gptkb:Silodyx
Urorec |
| gptkbp:CASNumber |
160970-54-7
|
| gptkbp:chemicalFormula |
C25H32F3N3O4
|
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to silodosin |
| gptkbp:drugClass |
alpha-1 adrenergic receptor antagonist
|
| gptkbp:eliminationHalfLife |
13 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericName |
gptkb:silodosin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rapaflo
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Watson_Pharmaceuticals
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
495.54 g/mol
|
| gptkbp:pregnancyCategory |
B1 (Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
dizziness nasal congestion retrograde ejaculation |
| gptkbp:usedFor |
gptkb:benign_prostatic_hyperplasia
|
| gptkbp:bfsParent |
gptkb:Silodosin
|
| gptkbp:bfsLayer |
8
|